Silo pharma expands intellectual property portfolio with patent application for exclusively licensed alzheimer's drug

Sarasota, fl, april 28, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the u.s. patent and trademark office (uspto) focused on the neurology drug spc-14, an intranasal compound for the treatment of alzheimer's disease (ad) exclusively licensed to silo pharma from columbia university.
SILO Ratings Summary
SILO Quant Ranking